title: Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin.
abstract: OBJECTIVE
  Compare lipid response, side effect profile and toxicity of younger (less than 50 years) versus older (50 to 70 years) hypercholesterolemic subjects taking wax-matrix sustained-release niacin (Endur-acin).
  
  
  METHODS
  An 8-week randomized double-blind placebo controlled trial.
  
  
  METHODS
  General community.
  
  
  METHODS
  Volunteers from community cholesterol screening programs and chart review of patients at family practice clinics. Male and female subjects, age 20 to 70, with baseline low density lipoprotein cholesterol level within the 75th to 95th percentile, excluded if on medications that affect lipids or if a history of diabetes, gout, peptic disease, or liver disease is present.
  
  
  METHODS
  Nicotinic acid dosage schedules were 1,000 mg/day, 1,250 mg/day, 1,500 mg/day, or 2,000 mg/day for 8 weeks.
  
  
  METHODS
  Change in blood lipids and blood chemistries, side effects, and pill compliance.
  
  
  RESULTS
  158 subjects (79%) completed the study. Higher dose groups (1,500 mg and 2,000 mg) demonstrated improvements in total cholesterol, LDL-cholesterol, HDL cholesterol, and total-to-HDL-cholesterol ratio (P less than 0.05) compared to baseline and controls. Higher-dose older subjects demonstrated significantly greater improvements than younger subjects on comparable doses for total cholesterol, HDL cholesterol, total-to-HDL-cholesterol ratio, and triglycerides, P less than 0.02). Adherence to medication schedules was better and incidence of side effects and toxicity no greater in older subjects compared to younger.
  
  
  CONCLUSIONS
  Wax-matrix niacin (Endur-acin) was shown to be effective and well tolerated for the pharmacological treatment of hypercholesterolemia. Older persons, ages 50 to 70, appear to experience greater benefits with no greater side effects when compared to younger subjects on similar doses.
authors.affiliation: Department of Family Practice and Community Health, University of Minnesota, Minneapolis 55414.
authors.forename: J M
authors.initials: JM
authors.lastname: Keenan
authors.forename: C Y
authors.initials: CY
authors.lastname: Bae
authors.forename: P L
authors.initials: PL
authors.lastname: Fontaine
authors.forename: J B
authors.initials: JB
authors.lastname: Wenz
authors.forename: S
authors.initials: S
authors.lastname: Myers
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Huang
authors.forename: C
authors.initials: C
authors.lastname: Ripsin
mesh_terms: D000328:Adult; D000368:Aged; D000375:Aging / Q000378:metabolism; D000469:Alkaline Phosphatase / Q000097:blood; D001786:Blood Glucose; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy*; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D009525:Niacin; D007770:L-Lactate Dehydrogenase; D000469:Alkaline Phosphatase